SUPERNUS PHARMACEUTICALS, INC.

SUPN

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Sep 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
2400mg SPN-804	Phase 3	Epilepsies, Partial	-
400mg SPN-812	Phase 3	ADHD	-
Oxcarbazepine XR	Phase 3	Partial Epilepsy	-
SAGE-547 90 μg/kg/h	Phase 3	Postpartum Depression	-
SAGE-547 60 μg/kg/h	Phase 3	Postpartum Depression	-
SPN-810 (36 mg)	Phase 3	Attention Deficit Hyperactivity Disorder (ADHD)	-
SPN-812	Phase 3	Attention-Deficit/Hyperactivity Disorder	-
SPN-810 (18 mg)	Phase 3	Attention Deficit Hyperactivity Disorder (ADHD)	-
200mg SPN-812	Phase 3	ADHD	-
MYOBLOC	Phase 3	Sialorrhea	-
100mg SPN-812	Phase 2	Attention-Deficit/Hyperactivity Disorder (ADHD)	-
TPM XR	Phase 2	Epilepsy	-
Brexanolone	Phase 2	Tinnitus	-
SAGE-718-matching placebo	Phase 2	Parkinson Disease	-
SAGE-718	Phase 2	Alzheimer Disease	-
Molindone	Phase 2	Impulsive Aggression Comorbid With ADHD in Children	-
BIS-001ER	Phase 2	Focal Impaired Awareness Seizures	-
Placebo	Phase 2	Severe Postpartum Depression	-
SPN-817	Phase 2	Focal Onset Seizures	-
IR Viloxazine	Phase 2	Attention-Deficit/Hyperactivity Disorder (ADHD)	-
SPN-810	Phase 2	Attention Deficit Disorder With Hyperactivity	-
SAGE-547	Phase 2	Postpartum Depression	-

Catalyst Timeline

3 upcoming, 0 past

⭐Phase 3Next

September 2026~SPN-812

Primary completion for SPN-812 trial (NCT02736656) in Attention-Deficit/Hyperactivity Disorder

Phase 2

October 2026~Placebo

Primary completion for Placebo trial (NCT06798896) in Focal Onset Seizures

Phase 2

October 2026~SPN-817

Primary completion for SPN-817 trial (NCT06798896) in Focal Onset Seizures

Regulatory Approvals

SUPN News